Author:
Yan Junbin,Nie Yunmeng,Chen Xinli,Ding Menglu,Zhang Shuo
Funder
National Natural Science Foundation of China
Zhejiang Province Department of Education
Reference40 articles.
1. Administration, F.D., 2005. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers.
2. From NASH to HCC: current concepts and future challenges;Anstee;Nat. Rev. Gastroenterol. Hepatol.,2019
3. Hepatic stellate cells role in the course of metabolic disorders development - A molecular overview;Bourebaba;Pharmacol. Res.,2021
4. Expert consensus on traditional chinese medicine diagnosis and treatment of non-aLcoholic fatty liver disease(2023);Chin. J. Integr. Tradit. West Med. Dig.,2024
5. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD);Buzzetti;Metabolism.,2016